(VRTX) Vertex Pharmaceuticals - Ratings and Ratios
Cystic Fibrosis, Sickle Cell, Beta Thalassemia, Acute Pain, Diabetes
VRTX EPS (Earnings per Share)
VRTX Revenue
Description: VRTX Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a biotechnology company that focuses on developing and commercializing therapies for treating cystic fibrosis (CF) and other serious diseases. The companys CF portfolio includes several approved treatments, such as TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target various patient populations and mutations.
From a clinical perspective, Vertex has a robust pipeline with multiple programs in various stages of development. Notable examples include CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia, JOURNAVX for acute pain, and several other programs targeting diseases such as Type 1 Diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. The companys collaborations with CRISPR Therapeutics AG, Moderna, Inc., and Entrada Therapeutics, Inc. further enhance its research and development capabilities.
Key performance indicators (KPIs) that can be used to evaluate Vertex Pharmaceuticals success include revenue growth, particularly from its CF franchise, as well as the expansion of its pipeline through successful clinical trials and regulatory approvals. Other relevant KPIs include the companys ability to maintain a strong market presence, its research and development expenses as a percentage of revenue, and its return on equity (ROE). Notably, Vertexs current ROE is -6.25, indicating that the company is currently investing heavily in its growth initiatives. With a forward P/E ratio of 24.94, the market expects Vertex to deliver strong earnings growth in the future.
From a financial perspective, Vertex Pharmaceuticals has a market capitalization of $114.3 billion, indicating its position as a significant player in the biotechnology industry. The companys stock price has shown volatility, with an average true range (ATR) of 1.83%, and has traded between $396.64 and $516.74 over the past 52 weeks. As a Trading Analyst, it is essential to monitor these KPIs and adjust expectations accordingly to make informed investment decisions.
VRTX Stock Overview
| Market Cap in USD | 99,621m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1991-07-24 |
VRTX Stock Ratings
| Growth Rating | 24.9% |
| Fundamental | 84.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -32.1% |
| Analyst Rating | 3.85 of 5 |
VRTX Dividends
Currently no dividends paidVRTX Growth Ratios
| Growth Correlation 3m | -60.7% |
| Growth Correlation 12m | -38.8% |
| Growth Correlation 5y | 92.5% |
| CAGR 5y | 11.46% |
| CAGR/Max DD 3y | 0.39 |
| CAGR/Mean DD 3y | 2.26 |
| Sharpe Ratio 12m | 0.86 |
| Alpha | 0.11 |
| Beta | 0.444 |
| Volatility | 23.23% |
| Current Volume | 2040.9k |
| Average Volume 20d | 1404.8k |
| Stop Loss | 375.5 (-3%) |
| Signal | -0.77 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (3.64b TTM) > 0 and > 6% of Revenue (6% = 685.1m TTM) |
| FCFTA 0.15 (>2.0%) and ΔFCFTA -1.73pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 55.08% (prev 52.20%; Δ 2.88pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.16 (>3.0%) and CFO 3.85b > Net Income 3.64b (YES >=105%, WARN >=100%) |
| Net Debt (-4.86b) to EBITDA (4.67b) ratio: -1.04 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.52 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (258.9m) change vs 12m ago 0.31% (target <= -2.0% for YES) |
| Gross Margin 86.11% (prev 86.44%; Δ -0.33pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 51.71% (prev 51.33%; Δ 0.37pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 258.2 (EBITDA TTM 4.67b / Interest Expense TTM 17.0m) >= 6 (WARN >= 3) |
Altman Z'' 7.96
| (A) 0.26 = (Total Current Assets 10.43b - Total Current Liabilities 4.14b) / Total Assets 24.04b |
| (B) 0.70 = Retained Earnings (Balance) 16.92b / Total Assets 24.04b |
| (C) 0.20 = EBIT TTM 4.39b / Avg Total Assets 22.08b |
| (D) 2.49 = Book Value of Equity 17.07b / Total Liabilities 6.86b |
| Total Rating: 7.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 84.31
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 3.50% = 1.75 |
| 3. FCF Margin 30.65% = 7.50 |
| 4. Debt/Equity 0.40 = 2.42 |
| 5. Debt/Ebitda 1.47 = 1.01 |
| 6. ROIC - WACC (= 32.26)% = 12.50 |
| 7. RoE 22.14% = 1.85 |
| 8. Rev. Trend 96.76% = 7.26 |
| 9. EPS Trend -9.48% = -0.47 |
What is the price of VRTX shares?
Over the past week, the price has changed by -0.36%, over one month by -0.70%, over three months by -12.41% and over the past year by -19.55%.
Is Vertex Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VRTX is around 351.34 USD . This means that VRTX is currently overvalued and has a potential downside of -9.25%.
Is VRTX a buy, sell or hold?
- Strong Buy: 14
- Buy: 4
- Hold: 14
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the VRTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 479.6 | 23.9% |
| Analysts Target Price | 479.6 | 23.9% |
| ValueRay Target Price | 388.8 | 0.4% |
Last update: 2025-09-12 04:47
VRTX Fundamental Data Overview
CCE Cash And Equivalents = 6.38b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 27.6155
P/E Forward = 19.8807
P/S = 8.7243
P/B = 5.8002
P/EG = 0.5801
Beta = 0.439
Revenue TTM = 11.42b USD
EBIT TTM = 4.39b USD
EBITDA TTM = 4.67b USD
Long Term Debt = 2.72b USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 4.14b USD (from totalCurrentLiabilities, last quarter)
Debt = 6.86b USD (Calculated: Short Term 4.14b + Long Term 2.72b)
Net Debt = -4.86b USD (from netDebt column, last quarter)
Enterprise Value = 100.10b USD (99.62b + Debt 6.86b - CCE 6.38b)
Interest Coverage Ratio = 258.2 (Ebit TTM 4.39b / Interest Expense TTM 17.0m)
FCF Yield = 3.50% (FCF TTM 3.50b / Enterprise Value 100.10b)
FCF Margin = 30.65% (FCF TTM 3.50b / Revenue TTM 11.42b)
Net Margin = 31.86% (Net Income TTM 3.64b / Revenue TTM 11.42b)
Gross Margin = 86.11% ((Revenue TTM 11.42b - Cost of Revenue TTM 1.59b) / Revenue TTM)
Tobins Q-Ratio = 5.86 (Enterprise Value 100.10b / Book Value Of Equity 17.07b)
Interest Expense / Debt = 0.05% (Interest Expense 3.70m / Debt 6.86b)
Taxrate = 315.5% (set to none) (784.1m / 248.5m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.52 (Total Current Assets 10.43b / Total Current Liabilities 4.14b)
Debt / Equity = 0.40 (Debt 6.86b / last Quarter total Stockholder Equity 17.18b)
Debt / EBITDA = 1.47 (Net Debt -4.86b / EBITDA 4.67b)
Debt / FCF = 1.96 (Debt 6.86b / FCF TTM 3.50b)
Total Stockholder Equity = 16.43b (last 4 quarters mean)
RoA = 15.13% (Net Income 3.64b, Total Assets 24.04b )
RoE = 22.14% (Net Income TTM 3.64b / Total Stockholder Equity 16.43b)
RoCE = 22.92% (Ebit 4.39b / (Equity 16.43b + L.T.Debt 2.72b))
RoIC = 32.26% (Ebit 4.39b / (Assets 24.04b - Current Assets 10.43b))
WACC = unknown (E(99.62b)/V(106.48b) * Re(7.65%)) + (D(6.86b)/V(106.48b) * Rd(0.05%) * (1-Tc(none)))
Shares Correlation 3-Years: 6.15 | Cagr: -0.02%
Discount Rate = 7.65% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 76.70% ; FCFE base≈3.41b ; Y1≈3.08b ; Y5≈2.67b
Fair Price DCF = 187.7 (DCF Value 48.13b / Shares Outstanding 256.4m; 5y FCF grow -12.03% → 3.0% )
EPS Correlation: -9.48 | EPS CAGR: 4.45% | SUE: 0.05 | # QB: 0
Revenue Correlation: 96.76 | Revenue CAGR: 9.08% | SUE: N/A | # QB: None
Additional Sources for VRTX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle